BiotechTube
Telesis Bio

Telesis Bio

TBIO
San Diego, United States· Est.
telesisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

TBIO · Stock Price

USD 0.05+0.04 (+325.00%)
Market Cap: $98K

Historical price data

Overview

Telesis Bio is a public company (NASDAQ: TBIO) commercializing automated platforms for in-lab DNA and mRNA synthesis, aiming to disrupt the traditional, slow outsourcing model. Its technology is anchored by two main platforms: the Gibson SOLA enzymatic synthesis system for high-throughput, high-fidelity builds, and the BioXp benchtop DNA printer for automated workflow consolidation. The company's strategy focuses on enabling faster iteration in key therapeutic areas like antibody discovery, cell & gene therapy, and vaccine development by giving scientists direct control over their synthetic biology processes.

Antibody DiscoveryCell & Gene TherapyVaccine Development

Technology Platform

The Gibson SOLA enzymatic synthesis platform for high-fidelity, automated DNA/mRNA synthesis integrated with lab robotics, and the BioXp benchtop system for consolidated, automated DNA printing workflows.

Opportunities

The accelerating convergence of AI and biology creates demand for rapid, high-throughput DNA synthesis to generate training data and test AI-generated designs.
Furthermore, the sustained growth in mRNA therapeutics, cell therapies, and personalized medicine drives need for decentralized, flexible, and rapid gene writing capabilities directly within R&D and manufacturing labs.

Risk Factors

The company faces severe financial risk with a depressed public market valuation, threatening its liquidity and ability to fund operations.
Commercial adoption risk is high, as it requires customers to shift from a variable-cost outsourcing model to a significant capital expenditure.
It also competes against well-funded incumbents in both the service and instrument synthesis markets.

Competitive Landscape

Telesis Bio competes directly with DNA synthesis service giants like Twist Bioscience and GenScript, and with instrument-focused peers like DNA Script. Its differentiation hinges on the legacy Gibson Assembly brand, integration with standard lab automation (Beckman Coulter), and a claimed seamless path from discovery to GMP production using a single chemistry.

More companies in Synthetic Biology →More companies in United States →